NO2914282T3 - - Google Patents

Info

Publication number
NO2914282T3
NO2914282T3 NO13811605A NO13811605A NO2914282T3 NO 2914282 T3 NO2914282 T3 NO 2914282T3 NO 13811605 A NO13811605 A NO 13811605A NO 13811605 A NO13811605 A NO 13811605A NO 2914282 T3 NO2914282 T3 NO 2914282T3
Authority
NO
Norway
Application number
NO13811605A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2914282T3 publication Critical patent/NO2914282T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO13811605A 2012-10-31 2013-10-31 NO2914282T3 (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
NO2914282T3 true NO2914282T3 (en:Method) 2018-05-19

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13811605A NO2914282T3 (en:Method) 2012-10-31 2013-10-31

Country Status (26)

Country Link
US (1) US10030238B2 (en:Method)
EP (3) EP3673914B1 (en:Method)
JP (2) JP2019068823A (en:Method)
KR (2) KR102264478B1 (en:Method)
CN (2) CN110499321A (en:Method)
AR (2) AR093309A1 (en:Method)
AU (3) AU2013340610B2 (en:Method)
BR (1) BR112015005384A2 (en:Method)
CA (1) CA2885519A1 (en:Method)
DK (2) DK2914282T3 (en:Method)
EA (1) EA201590794A8 (en:Method)
ES (2) ES2662402T3 (en:Method)
GB (1) GB201219602D0 (en:Method)
HU (2) HUE036764T2 (en:Method)
IL (1) IL237623B (en:Method)
IN (1) IN2015MN00436A (en:Method)
MX (2) MX367080B (en:Method)
NO (1) NO2914282T3 (en:Method)
NZ (1) NZ705575A (en:Method)
PL (2) PL2914282T3 (en:Method)
PT (2) PT2914282T (en:Method)
SG (2) SG10201701140WA (en:Method)
TW (3) TWI626307B (en:Method)
UA (1) UA118837C2 (en:Method)
WO (1) WO2014068317A1 (en:Method)
ZA (1) ZA201501449B (en:Method)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
EP3981783A1 (en) * 2015-03-26 2022-04-13 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
KR20180114891A (ko) 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019007509A1 (en) 2017-07-06 2019-01-10 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
SG11202003229RA (en) 2017-10-11 2020-05-28 Illustris Pharmaceuticals Inc Methods and compositions for topical delivery
TWI869073B (zh) * 2018-01-29 2025-01-01 英商艾普森生物製藥有限公司 非神經元性ＳＮＡＲＥ裂解的肉毒桿菌神經毒素、裂解ｈＳＮＡＰ-２３之活體外方法、及經修飾ＢｏＮＴ／Ａ Ｌ鏈蛋白酶之用途
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
US6495143B2 (en) 1998-07-10 2002-12-17 The United States Of America As Represented By The Secretary Of The Army Botulinum neurotoxin vaccine
DE60032367T3 (de) * 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
DK1853623T3 (da) * 2005-03-03 2013-07-15 Allergan Inc Dyreprodukt-frit system og fremgangsmåde til oprensning af et botulinumtoksin
DK1926744T4 (en) * 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
EP2038299A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CN102481351B (zh) * 2009-04-14 2015-05-13 Mcw研究基金会股份有限公司 工程改造的肉毒杆菌神经毒素
EP2512505A2 (en) * 2009-12-16 2012-10-24 Allergan, Inc. Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
CN110072880B (zh) * 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素

Also Published As

Publication number Publication date
NZ705575A (en) 2019-08-30
KR20150094590A (ko) 2015-08-19
EP3326644A1 (en) 2018-05-30
PL3326644T3 (pl) 2020-08-24
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
EP3326644B1 (en) 2020-03-04
SG10201701140WA (en) 2017-04-27
GB201219602D0 (en) 2012-12-12
EP2914282A1 (en) 2015-09-09
TWI673361B (zh) 2019-10-01
SG11201502372SA (en) 2015-05-28
TWI626307B (zh) 2018-06-11
EP2914282B1 (en) 2017-12-20
IL237623B (en) 2019-05-30
PL2914282T3 (pl) 2018-07-31
BR112015005384A2 (pt) 2017-08-08
JP2020078321A (ja) 2020-05-28
JP2019068823A (ja) 2019-05-09
AU2020244481A1 (en) 2020-10-29
TW202012622A (zh) 2020-04-01
MX2019009222A (es) 2019-11-21
AU2013340610A1 (en) 2015-03-19
IN2015MN00436A (en:Method) 2015-09-04
AU2018203556B2 (en) 2020-08-20
CN104755098A (zh) 2015-07-01
US10030238B2 (en) 2018-07-24
WO2014068317A1 (en) 2014-05-08
DK3326644T3 (da) 2020-05-11
TW201825680A (zh) 2018-07-16
IL237623A0 (en) 2015-04-30
US20150247139A1 (en) 2015-09-03
PT2914282T (pt) 2018-03-13
CA2885519A1 (en) 2014-05-08
ES2788199T3 (es) 2020-10-20
EA201590794A1 (ru) 2015-08-31
EP3673914A1 (en) 2020-07-01
DK2914282T3 (en) 2018-02-26
AR093309A1 (es) 2015-05-27
AU2013340610B2 (en) 2018-02-22
ZA201501449B (en) 2016-08-31
UA118837C2 (uk) 2019-03-25
TW201435084A (zh) 2014-09-16
PT3326644T (pt) 2020-05-29
KR102188539B1 (ko) 2020-12-09
EP3673914B1 (en) 2021-10-27
EA201590794A8 (ru) 2016-01-29
KR102264478B1 (ko) 2021-06-15
HK1208359A1 (en) 2016-03-04
MX367080B (es) 2019-08-05
HUE048802T2 (hu) 2020-08-28
AU2018203556A1 (en) 2018-06-07
MX2015005156A (es) 2015-09-23
CN110499321A (zh) 2019-11-26
KR20200110470A (ko) 2020-09-23
AR117738A2 (es) 2021-08-25

Similar Documents

Publication Publication Date Title
BR112014017635A2 (en:Method)
BR112014017708A2 (en:Method)
BR112014021401A2 (en:Method)
BR112014017659A2 (en:Method)
BR112014017592A2 (en:Method)
BR112014019235A2 (en:Method)
BR112014017646A2 (en:Method)
BR112014019610A2 (en:Method)
BR112014017638A2 (en:Method)
AR092201A1 (en:Method)
BR112013027865A2 (en:Method)
BR112014017609A2 (en:Method)
BR112014017634A2 (en:Method)
BR112014017644A2 (en:Method)
NO2914282T3 (en:Method)
BR112014017588A2 (en:Method)
BR112014017647A2 (en:Method)
BR112014013184A8 (en:Method)
BR112014017652A2 (en:Method)
BR112014025069A2 (en:Method)
BR112014017630A2 (en:Method)
BR112014024269A2 (en:Method)
BR112014017631A2 (en:Method)
BR112014017641A2 (en:Method)
BR112014017589A2 (en:Method)